AURORA CANNABIS INC (ACB)
Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels. For medical users, Aurora provides a diverse selection of products such as different strains of dried cannabis, cannabis oils, capsules, and topical kits. Their inventory also includes ancillary items like vaporizers, vaporizer accessories, herb mills (specifically for CanniMed products), grinders, and secure containers for vaporizers. The company is actively involved in developing advanced medical cannabis products, with ongoing work on oral, topical, edible, and inhalable formulations. Furthermore, Aurora manages CanvasRX, a network of centers dedicated to cannabis counseling and community outreach. Its service portfolio extends to providing patient support, specialized design and construction services, and comprehensive analytical testing for cannabis products. Aurora Cannabis Inc. manages an extensive collection of brands, including Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The company's main corporate office is located in Edmonton, Canada.
Sector: Medicinal Chemicals & Botanical Products
Industry: Drug Manufacturers - Specialty & Generic
Aurora Cannabis Inc.
| Form | Description | Links | |
|---|---|---|---|
| 6-K | |||
| 6-K | |||
| 6-K | |||
| SC14D9F/A | |||
| 6-K | |||
| 6-K | |||
| SC14D9F/A | |||
| 6-K | |||
| SC14D9F/A | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| SC14D9F/A | |||
| SC14D9F/A | |||
| SC14D1F/A | |||
| 425 | |||
| 6-K | |||
| SC14D9F/A | |||
| 6-K | |||
| 6-K | |||
| SC14D9F/A | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| F-X |
1-25 of 433 filings
Recent SEC filings with analysis
- 6-KAurora Cannabis reported fiscal Q2 2027 results while confirming that Organigram Global will acquire all outstanding Aurora shares under an Arrangement…
- 6-KAurora Cannabis filed its fiscal Q2 2027 interim results via 6-K, reporting quarterly revenue of C$89.2 million (net revenue C$86.0 million, up from C$78.8…
- 6-KAurora Cannabis has signed a definitive arrangement agreement to be acquired by Organigram, with Aurora shareholders to receive C$7.80 per share in total…
- 6-KAurora Cannabis has agreed to be acquired by Organigram Global for C$7.80 per share in a deal valuing Aurora at roughly C$561 million on a fully diluted basis,…
- 6-KAurora Cannabis announced it will host its fiscal Q2 2027 investor conference call on Thursday, November 12, 2026 at 8:00 a.m.
- 6-KAurora Cannabis announced that the Alberta Securities Commission dismissed Curaleaf's application to halt Aurora's at-the-market program, confirming the…
- 6-KAurora Cannabis' Board, on the unanimous recommendation of its Special Committee, reaffirmed its recommendation that shareholders REJECT Curaleaf's revised…
- 6-KAurora Cannabis completed a major expansion of its EU-GMP certified manufacturing facility in Leuna, Germany, now renamed Aurora Horizon, more than doubling…